Drug Profile
RO 273225
Latest Information Update: 16 Mar 2007
Price :
$50
*
At a glance
- Originator Roche
- Class Obesity therapies
- Mechanism of Action Melanocortin type 4 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 16 Mar 2007 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 12 Jun 2001 No-Development-Reported for Obesity in USA (Unknown route)
- 17 Dec 1998 New profile